Mind Pharmaceuticals
- Biotech or pharma, therapeutic R&D
Mind Pharmaceuticals Corporation, based in New Haven, is a clinical stage biotechnology company focused on psychedelic based therapeutic drugs to treat hard to treat psychiatry and CNS diseases.
The company is leveraging Yale University intellectual property and clinical trial data (N=52 completed, N>100 being recruited into ongoing studies), to bring rapid acting, sustained efficacy and scalable therapies for high burden conditions, such as treatment-resistant depression (TRD), migraine, and cluster headaches into later-stage development.
Its clinical-stage pipeline includes IV DMT (MIND001) for TRD, sub-psychedelic dose psilocybin (MIND002) for Migraine prevention and for cluster prevention, and non-psychedelic DMT formulations (MIND003).
The strategy is modeled after Spravato (esketamine), with scalable clinical delivery models, minimal psychotherapy and leveraging REMS to drive market exclusivity.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}